Vedanta Biosciences Stock

Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.

Sign up today and learn more about Vedanta Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Vedanta Biosciences Stock

Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.

Funding History

June 2016$50.0M
November 2017$5.4M

Management

Scientific Co-Founder

Dan Littman

Scientific Co-Founder

Alexander Rudensky

Chief Executive Officer

Bernat Olle

Co-founder

David Steinberg

Co-Founder & Chair

Ruslan Medzhitov

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo